Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Focus on Endpoints

Basic Details
Date
Tuesday, August 4, 2020
Type
Presentation
Description

This presentation was given at the Reagan-Udall Foundation and Friends of Cancer Research COVID-19 Diagnostics Evidence Accelerator Parallel Analysis meeting by Vincent Lo Re from the University of Pennsylvania on behalf of the FDA Sentinel COVID-19 Coagulopathy workgroup. It includes updates to the specific aims previously presented on the June 5, 2020 and July 15, 2020 meetings such as the evaluation of arterial and venous thrombotic events separately and study outcomes considerations.

Presenter(s)

Vincent Lo Re